Your browser doesn't support javascript.
loading
Examining the synergistic effects of a cognitive control video game and a home-based, self-administered non-invasive brain stimulation on alleviating depression: the DiSCoVeR trial protocol.
Dechantsreiter, Esther; Padberg, Frank; Morash, Alon; Kumpf, Ulrike; Nguyen, Arthur; Menestrina, Zeno; Windel, Fabienne; Burkhardt, Gerrit; Goerigk, Stephan; Morishita, Takuya; Soldini, Aldo; Ahissar, Shira; Cohen, Tamar; Pasqualotto, Angela; Rubene, Linda; Konosonoka, Liene; Keeser, Daniel; Zill, Peter; Assi, Razan; Gardier, Rémy; Viñals, Roser; Thiran, Jean-Philippe; Segman, Ronen; Benjamini, Yuval; Bonne, Omer; Hummel, Friedhelm Christoph; Bavelier, Daphne; Rancans, Elmars; Nahum, Mor.
Affiliation
  • Dechantsreiter E; Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich, Nussbaumstr. 7, 80336, Munich, Germany.
  • Padberg F; Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich, Nussbaumstr. 7, 80336, Munich, Germany. padberg@med.uni-muenchen.de.
  • Morash A; NeuroImaging Core Unit Munich (NICUM), University Hospital LMU, Munich, Germany. padberg@med.uni-muenchen.de.
  • Kumpf U; Hadassah Medical Center, Jerusalem, Israel.
  • Nguyen A; Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich, Nussbaumstr. 7, 80336, Munich, Germany.
  • Menestrina Z; Faculty of Psychology and Educational Sciences, University of Geneva, and Campus Biotech, Geneva, Switzerland.
  • Windel F; Faculty of Psychology and Educational Sciences, University of Geneva, and Campus Biotech, Geneva, Switzerland.
  • Burkhardt G; Defitech Chair of Clinical Neuroengineering, Neuro-X Institute (INX) and Brain Mind Institute (BMI), Ecole Polytechnique Fédérale de Lausanne (EPFL), Geneva, Switzerland.
  • Goerigk S; Defitech Chair for Clinical Neuroengineering, INX and BMI, EPFL Valais, Clinique Romande de Réadaptation, Sion, Switzerland.
  • Morishita T; Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich, Nussbaumstr. 7, 80336, Munich, Germany.
  • Soldini A; Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich, Nussbaumstr. 7, 80336, Munich, Germany.
  • Ahissar S; Department of Psychological Methodology and Assessment, Ludwig-Maximilians-University, Leopoldstraße 13, 80802, Munich, Germany.
  • Cohen T; Charlotte Fresenius Hochschule, Infanteriestraße 11A, 80797, Munich, Germany.
  • Pasqualotto A; Defitech Chair of Clinical Neuroengineering, Neuro-X Institute (INX) and Brain Mind Institute (BMI), Ecole Polytechnique Fédérale de Lausanne (EPFL), Geneva, Switzerland.
  • Rubene L; Defitech Chair for Clinical Neuroengineering, INX and BMI, EPFL Valais, Clinique Romande de Réadaptation, Sion, Switzerland.
  • Konosonoka L; Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich, Nussbaumstr. 7, 80336, Munich, Germany.
  • Keeser D; School of Occupational Therapy, Faculty of Medicine, The Hebrew University, Jerusalem, Israel.
  • Zill P; School of Occupational Therapy, Faculty of Medicine, The Hebrew University, Jerusalem, Israel.
  • Assi R; Faculty of Psychology and Educational Sciences, University of Geneva, and Campus Biotech, Geneva, Switzerland.
  • Gardier R; Department of Psychiatry and Narcology, Riga Stradins University, Riga, Latvia.
  • Viñals R; Riga Centre of Psychiatry and Addiction Disorders, Riga, Latvia.
  • Thiran JP; Department of Psychiatry and Narcology, Riga Stradins University, Riga, Latvia.
  • Segman R; Riga Centre of Psychiatry and Addiction Disorders, Riga, Latvia.
  • Benjamini Y; Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich, Nussbaumstr. 7, 80336, Munich, Germany.
  • Bonne O; NeuroImaging Core Unit Munich (NICUM), University Hospital LMU, Munich, Germany.
  • Hummel FC; Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich, Nussbaumstr. 7, 80336, Munich, Germany.
  • Bavelier D; School of Occupational Therapy, Faculty of Medicine, The Hebrew University, Jerusalem, Israel.
  • Rancans E; Signal Processing Laboratory 5 (LTS5), Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
  • Nahum M; Signal Processing Laboratory 5 (LTS5), Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
Eur Arch Psychiatry Clin Neurosci ; 273(1): 85-98, 2023 Feb.
Article de En | MEDLINE | ID: mdl-36271928
Enhanced behavioral interventions are gaining increasing interest as innovative treatment strategies for major depressive disorder (MDD). In this study protocol, we propose to examine the synergistic effects of a self-administered home-treatment, encompassing transcranial direct current stimulation (tDCS) along with a video game based training of attentional control. The study is designed as a two-arm, double-blind, randomized and placebo-controlled multi-center trial (ClinicalTrials.gov: NCT04953208). At three study sites (Israel, Latvia, and Germany), 114 patients with a primary diagnosis of MDD undergo 6 weeks of intervention (30 × 30 min sessions). Patients assigned to the intervention group receive active tDCS (anode F3 and cathode F4; 2 mA intensity) and an action-like video game, while those assigned to the control group receive sham tDCS along with a control video game. An electrode-positioning algorithm is used to standardize tDCS electrode positioning. Participants perform their designated treatment at the clinical center (sessions 1-5) and continue treatment at home under remote supervision (sessions 6-30). The endpoints are feasibility (primary) and safety, treatment efficacy (secondary, i.e., change of Montgomery-Åsberg Depression Rating Scale (MADRS) scores at week six from baseline, clinical response and remission, measures of social, occupational, and psychological functioning, quality of life, and cognitive control (tertiary). Demonstrating the feasibility, safety, and efficacy of this novel combined intervention could expand the range of available treatments for MDD to neuromodulation enhanced interventions providing cost-effective, easily accessible, and low-risk treatment options.ClinicalTrials.gov: NCT04953208.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Trouble dépressif majeur / Stimulation transcrânienne par courant continu Type d'étude: Clinical_trials / Guideline Aspects: Patient_preference Limites: Humans Langue: En Journal: Eur Arch Psychiatry Clin Neurosci Sujet du journal: NEUROLOGIA / PSIQUIATRIA Année: 2023 Type de document: Article Pays d'affiliation: Allemagne Pays de publication: Allemagne

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Trouble dépressif majeur / Stimulation transcrânienne par courant continu Type d'étude: Clinical_trials / Guideline Aspects: Patient_preference Limites: Humans Langue: En Journal: Eur Arch Psychiatry Clin Neurosci Sujet du journal: NEUROLOGIA / PSIQUIATRIA Année: 2023 Type de document: Article Pays d'affiliation: Allemagne Pays de publication: Allemagne